Vir Biotechnology (VIR) Operating Expenses (2018 - 2026)

Vir Biotechnology's Operating Expenses history runs 9 years deep, the most recent figure standing at $132.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 7.24% year-over-year to $132.3 million; the TTM figure through Mar 2026 stood at $537.6 million (down 19.46% YoY), while the FY2025 annual figure was $547.9 million, down 17.16% from the prior year.
• Operating Expenses came in at $132.3 million for Q1 2026 at Vir Biotechnology, up from $112.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $233.7 million in Q3 2024 to a low of $112.0 million in Q4 2025.
• A 5-year average of $170.3 million and a median of $173.7 million in 2025 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 59.06% in 2022 and slumped 33.86% in 2024, its largest moves.
• Vir Biotechnology's Operating Expenses stood at $199.9 million in 2022, then dropped by 22.06% to $155.8 million in 2023, then retreated by 16.87% to $129.5 million in 2024, then decreased by 13.54% to $112.0 million in 2025, then advanced by 18.1% to $132.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $132.3 million, $112.0 million, and $173.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison